Compare Mesoblast Limited (MESO) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tencent Music Entertainment Group - ADR — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while Tencent Music Entertainment Group - ADR trades at $9.03 (market cap $15.08B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 6.9× Mesoblast Limited's market cap, and Tencent Music Entertainment Group - ADR pays a 2.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | TME | |
|---|---|---|
Market Cap | $2.17B | $15.08B |
Sector | Technology | Media |
52-Week High | $20.96 | $26.36 |
52-Week Low | $12.88 | $8.16 |
Enterprise Value | $2.17B | $11.85B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
TME trades at $9.19, up 0.77% today, with a bullish technical signal from moving averages. The company reported strong 2025 results with revenue of $32.9B and net income of $11.1B, though recent quarterly earnings have missed expectations. Analyst consensus is mixed with 45.8% buy ratings and a $14 price target, while cash flow trends show significant investment activity.
The outlook remains cautiously optimistic with solid profitability metrics and ecosystem expansion through initiatives like SEND audio technology. Key risks include competitive pressures and execution challenges in premium content delivery. The stock presents value opportunity given reasonable valuation multiples relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
